Company intelligence / Profile preview

Vestar

San Dimas, California, United States

Ownership: Private
Development stage: Other

Overview

Vestar was a biopharmaceutical company specializing in the development of liposomal drug delivery systems to improve the efficacy and safety of therapeutic agents. The company is best known for developing AmBisome, a liposomal formulation of the antifungal amphotericin B, which became a gold standard for treating serious systemic fungal infections. Vestar also developed DaunoXome, a liposomal formulation of daunorubicin, for the treatment of HIV-associated Kaposi's sarcoma. In 1994, Vestar merged with NeXagen to form NeXstar Pharmaceuticals, which was subsequently acquired by Gilead Sciences in 1999.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Liposomal drug delivery therapySmall molecule
Industry: Biotech

Beyond the preview

Go deeper on Vestar.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vestar.

Explore the full profile